Across rare disease, patients continue to navigate serious conditions with few effective treatments. Hear from Renee Gala, President and CEO, on how we are sharpening our strategic focus to drive innovation and strengthen our commitment to delivering meaningful impact for patients and their families.
People diagnosed with locally advanced/metastatic HER2-positive gastroesophageal adenocarcinoma continue to face limited treatment options with the need to improve outcomes. Discover why innovation in the first-line setting remains essential to improving care. Lisa shares the story of her son Jace, who faced his diagnosis of a rare brain cancer with courage and compassion. His outlook continues to inspire the support Lisa now offers to other families navigating childhood cancer. Epilepsy is one of the most common neurological diseases in the world. While many treatments are available, there remains a significant unmet need among adult and pediatric patients who experience treatment-resistant seizures. Read more about how we are continuing to shine a light on the real-world burden associated with living with rare, treatment-resistant epileptic conditions.